New York, April 18, 2026, 14:34 EDT
Definium Therapeutics Inc. is heading into a heavy clinical-data stretch with fresh Wall Street backing, after Stifel analyst Paul Matteis initiated coverage of the Nasdaq-listed company with a Buy rating and a $30 price target. The focus is DT120 ODT, an orally disintegrating tablet form of lysergide D-tartrate, better known as LSD, now in late-stage trials for anxiety and depression.
The timing matters. Definium has scheduled an investor and analyst day in New York for April 22, where the company says management and outside clinical experts will discuss DT120, expected 2026 top-line data and the drug’s potential market opportunity. Top-line data means the first headline results from a clinical trial, before fuller analysis follows.
Definium says DT120 is being tested in four pivotal Phase 3 studies, two in generalized anxiety disorder, or GAD, and two in major depressive disorder, or MDD. Phase 3 is the late stage of human testing often used to support a possible marketing application. The company has guided to Emerge MDD data in late second quarter, Voyage GAD data in early third quarter and Panorama GAD data in the second half of 2026.
Shares last changed hands at $22.68, up 21 cents from the previous close, with the latest recorded trade after the U.S. market close on Friday. The stock has become a proxy for investor appetite in psychedelic medicine, a field still marked by high expectations and uneven regulatory history.
Matteis described GAD as a large “white space” in neuropsychiatry, where even modest penetration could imply a multibillion-dollar opportunity, according to Benzinga. He also flagged a practical issue: DT120 requires six to eight hours of in-office administration, making clinic capacity a core investor debate. benzinga.com
Chief Executive Rob Barrow has framed the drug as more than a symptom-control product. “We’re driving change on a different level,” he told PharmaVoice, adding that the goal was “not just symptom suppression.” The same report said patients would need trained clinical care after dosing, but Barrow said Spravato treatment centers could be a useful base if DT120 reaches the market. pharmavoice.com
The competitive backdrop is getting tighter. Johnson & Johnson reported $468 million in first-quarter worldwide sales for Spravato, its esketamine nasal spray for depression, up 46.4% from a year earlier, showing that supervised, clinic-based psychiatric drugs can scale. Compass Pathways, meanwhile, said in February that its COMP360 psilocybin program met the main goal in a second Phase 3 depression trial and that it expected to complete a U.S. submission in the fourth quarter.
Piper Sandler has also started coverage with an Overweight rating and a $49 price target, saying DT120 could represent a “best-in-class” opportunity in an emerging neuroplastogen market. Neuroplastogens are drugs aimed at changing neural pathways, not just lifting symptoms for a few hours. TipRanks
Definium has money to run the tests. The company reported $411.6 million in cash, cash equivalents and investments at the end of 2025 and said that was enough to fund operations into 2028. Barrow called 2026 a “monumental year” for Definium in February, when the company reported full-year results. Definium Therapeutics
But the path is narrow. Phase 3 trials can miss, regulators can ask for more data, and any LSD-containing product would face controlled-substance hurdles before U.S. marketing. Definium’s annual filing also notes competition from AtaiBeckley, Compass, GH Research, Johnson & Johnson and others, some of which have deeper financial and commercial resources.
There is also a legal overhang. Signant Health sued Definium in Delaware federal court in February, alleging trade-secret theft tied to LSD clinical trials; Definium denied the claims and said it would respond through the legal process, Reuters reported.
For now, Definium’s story is simple and difficult: the company has capital, analyst attention and a near-term calendar. The next step is less about narrative and more about trial results.
